Im not going to second-guess myself. Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like peptide-1 agonists) that have upended the treatment of obesity in recent years, offering hope to patients who have tried and failed to lose weight in myriad other ways
This medication belongs to the glucagon-like peptide-1 (GLP-1) receptor agonists, working by mimicking the effects of natural GLP-1 in the body
1 However, the industrialization of compounding, particularly through the Section 503B outsourcing facility model, has created a parallel manufacturing sector that operates largely outside the Abbreviated New Drug Application (ANDA) framework but competes directly with approved products
[DOI] [PMC free article] [PubMed] [Google Scholar] 2.Drucker DJ, Habener JF, Holst JJ
Across studies, these health markers returned to unhealthy baseline levels an average of a year and a half after treatment ended